Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Completes Genzyme Genetics Buy

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said that it has completed its acquisition of Genzyme Genetics.

LabCorp paid $925 million in cash for the unit of Genzyme. The deal, which was announced in September, includes all of Genzyme Genetics' testing services, technology, intellectual property rights, and nine testing laboratories.

In 2009, Genzyme Genetics brought in revenues of about $371 million. The menu of services it provides includes maternal serum screening, prenatal diagnostics, carrier screening, and postnatal testing.

LabCorp said the acquisition has a net cash cost of around $795 million — net of expected income tax benefits, less acquisition-related expenses.

"Closing the acquisition of Genzyme Genetics firmly establishes LabCorp as the premier genetics and oncology laboratory in the United States and further strengthens LabCorp's leadership position in personalized medicine." David King, chairman and CEO of LabCorp, said in a statement.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.